Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells
Cells · 2024
DOI: 10.3390/cells13201700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Pratheesh Kumar Poyil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Polo-Like Kinase 1, Colorectal Neoplasms, Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Polo-like kinase 1 (PLK1) is a serine/threonine–protein kinase essential for regulating multiple stages of cell cycle progression in mammals. Aberrant regulation of PLK1 has been observed in numerous human cancers and is linked to poor prognoses. However, its role in the pathogenesis of colorectal cancer (CRC) in the Middle East remains unexplored. PLK1 overexpression was noted in 60.3% (693/1149) of CRC cases and was significantly associated with aggressive clinico-pathological parameters and p-ERK1/2 overexpression. Intriguingly, multivariate logistic regression analysis identified PLK1 as an independent predictor of lymph node metastasis. Our in vitro experiments demonstrated that CRC cells with high PLK1 levels were resistant to 5-Fu treatment, while those with low PLK1 expression were sensitive. To investigate PLK1′s role in chemoresistance, we used the specific inhibitor volasertib, which effectively reversed 5-Fu resistance. Interestingly, forced PLK1 expression activated the CRAF-MEK-ERK signaling cascade, while its inhibition suppressed this cascade. PLK1 knockdown reduced epithelial-to-mesenchymal transition (EMT) progression and stem cell-like traits in 5-Fu-resistant cells, implicating PLK1 in EMT induction and stemness in CRC. Moreover, silencing ERK1/2 significantly mitigated chemoresistance, EMT, and stemness properties in CRC cell lines that express PLK1. Furthermore, the knockdown of Zeb1 attenuated EMT and stemness, suggesting a possible link between EMT activation and the maintenance of stemness in CRC. Our findings underscore the pivotal role of PLK1 in mediating chemoresistance and suggest that PLK1 inhibition may represent a potential therapeutic strategy for the management of aggressive colorectal cancer subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
- Department of Pathology, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
ORCID-Profile: Khawla S Al-Kuraya
Zitieren
APA
Poyil, P. K., Siraj, A. K., Padmaja, D., Parvathareddy, S. K., Alobaisi, K., Thangavel, S., Begum, R., Diaz, R., Al-Dayel, F., & Al-Kuraya, K. S. (2024). Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells. Cells. https://doi.org/10.3390/cells13201700
Vancouver
Poyil PK, Siraj AK, Padmaja D, Parvathareddy SK, Alobaisi K, Thangavel S, et al. Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells. Cells. 2024. doi:10.3390/cells13201700
BibTeX
@article{Poyil2024,
author = {Poyil, Pratheesh Kumar and Siraj, Abdul K and Padmaja, Divya and Parvathareddy, Sandeep Kumar and Alobaisi, Khadija and Thangavel, Saravanan and Begum, Rafia and Diaz, Roxanne and Al-Dayel, Fouad and Al-Kuraya, Khawla S},
title = {Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13201700}
}
EUVIMED